Please assess the completion status of the following clinical trial:

Trial Title: Impact of Denosumab in the Prevention of Bone Loss in Non-menopausal Women With Anorexia Nervosa

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Patients with a current AN defined by DSM-V criteria~* Being female~* Age over or equal to 18 years and less or equal to 40 years~  . For patients under 20 years of age, effective bone maturation (attested by a radiography of the hip)~* Agree to take contraception up to five months after the last injection of denosumab .~* Absence of pregnancy evidenced by an interview and a negative assay of human chorionic gonadotropin (ßhCG).~* Evidence of low BMD determined by Z-score value \< -2 DS (at least one site (lumbar spine or total proximal femur)~* Signing an informed consent.~Exclusion criteria:~* Not affiliated to a social security scheme or not being the beneficiary of such a scheme.~* Severe hepatic cytolysis with transaminase up to 5 times normal.~* Severe dental problems: in case of doubt an assessment by a dentist will be required before inclusion.~* Desire of pregnancy during the two years of follow-up study.~* Disease or treatment potentially responsible for secondary osteoporosis.~* Participant already treated with a molecule known to have an effect on bone~* Diabetes.~* Current hypocalcemia.~* Immunodeficiency.~* Cancer with bone lesions~* Patient on protectice measures (guardianship or trusteeship)~* Hypersensitivity to the active substance or to any of the excipients of Prolia®~* Unable to read and / or write and understand the methodology of the study~* Reporting relationship to the investigator~* Anticipate a long stay outside the region that would prevent compliance with the schedule of visits~* Participation to other biomedical research on health products~* Deprived of liberty~* Breastfeeding

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Denosumab subcutaneous injections (Type: ACTIVE_COMPARATOR): The treated group (n = 42) will receive Denosumab (60 mg, two subcutaneous injections at M0 and M6) associated with a daily treatment of vitamin D (800 IU) + calcium (1000 mg).
- Placebo subcutaneous injections (Type: PLACEBO_COMPARATOR): The control group (n = 42) will received a placebo injection (two subcutaneous injections at M0 and M6) with daily treatment of vitamin D (800 IU) +calcium (1000 mg).

Based on this trial design, predict the completion outcome and termination type (if applicable).